Tom Rozema

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · New England Journal of Medicine · 2012 · 5.3K citations · Full text

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.5K citations

Surgical Oncology, Neoadjuvant Chemoradiotherapy, Esophageal Cancer +9

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.5K citations · Full text

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +9

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · Journal of Clinical Oncology · 2021 · 709 citations · Full text

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 562 citations

Surgical Oncology, Chemotherapy Versus Chemoradiotherapy, Gastrointestinal Oncology +8